Bayesian Capital Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Bayesian Capital Management’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,393	Closed	-$12K	–	1197
2022 Q1	$12K	Buy	+2,393	New	+$15.1K	﹤0.01%	752

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bayesian Capital Management's EVFM Position: Q2 2022 in Review

Bayesian Capital Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 2,393 shares — an estimated $12K sold.

Bayesian Capital Management first reported a position in EVFM in Q1 2022 and held it in 1 quarter. The position peaked at $12K in Q1 2022. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

Bayesian Capital Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Bayesian Capital Management sold 2,393 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $12K.
Bayesian Capital Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
Bayesian Capital Management's Evofem Biosciences, Inc. Common Stock position peaked at $12K in Q1 2022.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.